The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Long–Term Renal Outcomes after Cisplatin Treatment
Open accessAbstract
Background and objectives: Nephrotoxicity remains the dose–limiting side effect of cisplatin, an effective chemotherapeutic agent with applications across diverse tumor types. This study presents data on renal outcomes across multiple tumor types in 821 adults. We report on incidence of AKI, initial and long-term changes in eGFR after cisplatin, and relationships between cumulative dose, initial eGFR, age, sex, and long–term renal function. Design, setting, participants, & measurements: This was a retrospective study of adult patients treated with cisplatin from January 1, 2000 to September 21, 2011 who had survived ≥5 years after initial dose. The Modification of Diet in Renal Disease equation was used to calculate eGFR. AKI was defined as an increase from the baseline creatinine of >25% within 30 days after the first cycle of cisplatin. Chi-squared tests were done to evaluate the relationships between categorical or ordinal variables; ANOVAs or t tests were used to evaluate continuous or categorical variables. Changes in eGFR over time were evaluated in a growth curve model. Results: Mean follow-up was 6 years (25th and 75th percentiles, 4 and 9 years). AKI occurred in 31.5% of patients, with a median initial decline in eGFR of 10 ml/min per 1.73 m 2 (25th and 75th percentiles, −41.5 and −23.3 ml/min per 1.73 m 2). At any time point after the first cycle of cisplatin, <3% of patients progressed to eGFR<29 ml/min per 1.73 m 2, and none were known to be on dialysis. Age was associated with a higher risk for AKI after cisplatin. Compared with age <25 years old, the odds ratios for AKI versus no AKI are 1.22 for >26–44 years old (95% confidence interval [95% CI], 0.60 to 2.4), 1.54 for >45–65 years old (95% CI, 0.78 to 3), and 2.96 for >66 years old (95% CI, 1.4 to 6.1). The lowest dose categories of cisplatin (≤100 and 101–250 mg/m 2) are associated with increases in eGFR (P=0.06 and P=0.02, respectively) compared with the highest dose category (>701 mg/m 2). Conclusions: This is the largest study of adult patients with cancer who received cisplatin for treatment across multiple tumor types. Most patients experience small but permanent declines in eGFR, but none progressed to ESRD requiring hemodialysis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arany, I., & Safirstein, R. L. (2003) · Seminars in Nephrology · doi:10.1016/s0270-9295(03)00089-5 · Cited by 906
The severity of acute kidney injury predicts progression to chronic kidney disease
Chawla, L. S., Amdur, R. L., Amodeo, S., Kimmel, P. L., & Palant, C. E. (2011) · Kidney International · doi:10.1038/ki.2011.42 · Cited by 738
Cisplatin and platinum drugs at the molecular level (Review)
Boulikas, T., & Vougiouka, M. (2003) · Oncology Reports · doi:10.3892/or.10.6.1663 · Cited by 729
Earley, A., Miskulin, D., Lamb, E. J., Levey, A. S., & Uhlig, K. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-11-201203200-00391 · Cited by 487
Madias, N. E., & Harrington, J. T. (1978) · The American Journal of Medicine · doi:10.1016/0002-9343(78)90825-2 · Cited by 453
Ishani, A., Nelson, D., Clothier, B., Schult, T., Nugent, S., Greer, N., Slinin, Y., & Ensrud, K. E. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.514 · Cited by 406
Long term effect of Cis-Diamminedichloride platinum (CDDP) on renal function and structure in man
Dentino, M. E., Luft, F. C., Yum, M. N., Williams, S. D., & Einhorn, L. H. (1978) · Cancer · Cited by 305
SEVERE NEUROTOXICITY, OTOTOXICITY AND NEPHROTOXICITY FOLLOWING HIGH-DOSE CISPLATIN AND AMIFOSTINE
Sastry, J., & Kellie, S. J. (2005) · Pediatric Hematology and Oncology · doi:10.1080/08880010590964381 · Cited by 258
Cisplatin-Associated Nephrotoxicity and Pathological Events
Taguchi, T., Nazneen, A., Abid, M. R., & Razzaque, M. S. (2005) · Contributions to Nephrology · doi:10.1159/000086055 · Cited by 256
DNA repair and cisplatin resistance in non-small-cell lung cancer
Rosell, R., Lord, R. V. N., Taron, M., & Reguart, N. (2002) · Lung Cancer · doi:10.1016/s0169-5002(02)00224-6 · Cited by 178
Long-term effects of chemotherapy in patients with testicular cancer.
Osanto, S., Bukman, A., van Hoek, F., Sterk, P. J., de Laat, J. A. P. M., & Hermans, J. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.4.574 · Cited by 143
Skinner, R., Parry, A., Price, L., Cole, M. F., Craft, A. W., & Pearson, A. D. J. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.06.032 · Cited by 126
Cisplatin dose rate as a risk factor for nephrotoxicity in children
Skinner, R., Pearson, A. D. J., English, M., Price, L., Wyllie, R., Coulthard, M., & Craft, A. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.276 · Cited by 112
Hypomagnesemia and Renal Magnesium Wasting in Patients Treated With Cisplatin
Lam, M., & Adelstein, D. J. (1986) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(86)80020-8 · Cited by 97
Boyer, M. J., Raghavan, D., Harris, P. J., Lietch, J., Bleasel, A., Walsh, J. C., Anderson, S., & Tsang, C. S. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.1.21 · Cited by 91
Lack of age-dependent cisplatin nephrotoxicity
Hrushesky, W. J. M., Shimp, W. S., & Kennedy, B. J. (1984) · The American Journal of Medicine · doi:10.1016/0002-9343(84)90280-8 · Cited by 86
Long-Term Renal Effect of Cisplatin in Man
Brilleta, G., Demya, G., Jacquiauda, C., et al. (1994) · American Journal of Nephrology · doi:10.1159/000168693 · Cited by 64
Renal toxicities of antineoplastic drugs and bone marrow transplantation.
Berns, J. S., & Ford, P. (1997) · PubMed · Cited by 39
Sm, J., Ho, P., Ws, K., Kang, D.-G., Hs, L., & Bh, J. (2014) · PubMed · Cited by 31
Meijer, S., Mulder, N. H., Sleijfer, D. T., et al. (2009) · Oncology · doi:10.1159/000225718 · Cited by 19
Cited by
Cisplatin nephrotoxicity: new insights and therapeutic implications
Tang, C., Livingston, M. J., Safirstein, R., & Dong, Z. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00631-7 · Cited by 548
Drug-Induced Acute Kidney Injury
Perazella, M. A., & Rosner, M. H. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11290821 · Cited by 357
Skinner, R. (2018) · Pediatric Nephrology · doi:10.1007/s00467-017-3662-z · Cited by 67
Metadata
- Authors
- Latcha, S., Jaimes, E. A., Patil, S., Glezerman, I. G., Mehta, S., & Flombaum, C. D.
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2016-04-12
- Volume
- 11
- Issue
- 7
- Pages
- 1173-1179
- ISSN
- 1555-9041 (ISSN-L)
- 1555-905X
- OpenAlex
- W2337424574
- Cited by
- 256
- References
- 20
- FWCI
- 9.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.